BioCentury
ARTICLE | Company News

Syntimmune deal helps Alexion diversify beyond Soliris

September 26, 2018 8:07 PM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.).

Alexion will pay $400 million up front for Syntimmune, and the company’s shareholders, which include founding institutional investor Apple Tree Partners, will be eligible for $800 million in milestones...